|
Advertisement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
J. Biol. Chem., Vol. 283, Issue 18, 11866-11875, May 2, 2008
The Inhalation Anesthetic Desflurane Induces Caspase Activation and Increases Amyloid β-Protein Levels under Hypoxic Conditions*![]() ¶1![]() 1![]() ||![]() ![]() ![]() ![]() ![]() ![]() ![]() 2![]() 3
From the
Perioperative factors including hypoxia, hypocapnia, and certain anesthetics have been suggested to contribute to Alzheimer disease (AD) neuropathogenesis. Desflurane is one of the most commonly used inhalation anesthetics. However, the effects of desflurane on AD neuropathogenesis have not been previously determined. Here, we set out to assess the effects of desflurane and hypoxia on caspase activation, amyloid precursor protein (APP) processing, and amyloid β-protein (Aβ) generation in H4 human neuroglioma cells (H4 naïve cells) as well as those overexpressing APP (H4-APP cells). Neither 12% desflurane nor hypoxia (18% O2) alone affected caspase-3 activation, APP processing, and Aβ generation. However, treatment with a combination of 12% desflurane and hypoxia (18% O2) (desflurane/hypoxia) for 6 h induced caspase-3 activation, altered APP processing, and increased Aβ generation in H4-APP cells. Desflurane/hypoxia also increased levels of β-site APP-cleaving enzyme in H4-APP cells. In addition, desflurane/hypoxia-induced Aβ generation could be reduced by the broad caspase inhibitor benzyloxycarbonyl-VAD. Finally, the Aβ aggregation inhibitor clioquinol and
Received for publication, January 9, 2008 , and in revised form, February 11, 2008. * This work was supported by Grant R37MH 60009 from the National Institutes of Health and the Cure Alzheimer's Fund (to R. E. T.) and by Grant K08 NS048140 from the National Institutes of Health, and Jahnigen Career Development Award from the American Geriatrics Society, an Investigator Initiated research grant from the Alzheimer's Association, and the William Milton Fund (Harvard University) (to Z. X.). The cost of the anesthetic desflurane and partial financial support of Yuanlin Dong and Bin Zhang were generously provided by the Department of Anesthesia and Critical Care in Massachusetts General Hospital and Harvard Medical School. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. 1 These authors contributed equally to this work. 2 To whom correspondence may be addressed: Genetics and Aging Research Unit, Massachusetts General Hospital/Harvard Medical School, 114 16th St., C3009, Charlestown, MA 02129-4404. Tel.: 617-726-6845; Fax: 617-724-1949; E-mail: tanzi{at}helix.mgh.harvard.edu. 3 To whom correspondence may be addressed: Genetics and Aging Research Unit, Dept. of Neurology, Dept. of Anesthesia and Critical Care, Massachusetts General Hospital/Harvard Medical School, 114 16th St., 3750, Charlestown, MA 02129-4404. Tel.: 617-724-9308; Fax: 617-724-1823; E-mail: zxie{at}partners.org.
This article has been cited by other articles:
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Advertisement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||